vs
Side-by-side financial comparison of Dexcom (DXCM) and Equity Residential (EQR). Click either name above to swap in a different company.
Dexcom is the larger business by last-quarter revenue ($1.3B vs $781.9M, roughly 1.6× Equity Residential). Equity Residential runs the higher net margin — 48.9% vs 21.2%, a 27.6% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 2.0%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 3.4%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Equity Residential is a United States–based publicly traded real estate investment trust that invests in apartments.
DXCM vs EQR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $781.9M |
| Net Profit | $267.3M | $382.1M |
| Gross Margin | 62.9% | — |
| Operating Margin | 25.6% | 50.6% |
| Net Margin | 21.2% | 48.9% |
| Revenue YoY | 21.6% | 2.0% |
| Net Profit YoY | 153.6% | -8.8% |
| EPS (diluted) | $0.67 | $1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $781.9M | ||
| Q3 25 | $1.2B | $782.4M | ||
| Q2 25 | $1.2B | $768.8M | ||
| Q1 25 | $1.0B | $760.8M | ||
| Q4 24 | $1.1B | $766.8M | ||
| Q3 24 | $994.2M | $748.3M | ||
| Q2 24 | $1.0B | $734.2M |
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $382.1M | ||
| Q3 25 | $283.8M | $289.1M | ||
| Q2 25 | $179.8M | $192.4M | ||
| Q1 25 | $105.4M | $256.6M | ||
| Q4 24 | $151.7M | $419.1M | ||
| Q3 24 | $134.6M | $143.4M | ||
| Q2 24 | $143.5M | $177.5M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 50.6% | ||
| Q3 25 | 20.1% | 38.5% | ||
| Q2 25 | 18.4% | 26.6% | ||
| Q1 25 | 12.9% | 35.7% | ||
| Q4 24 | 17.0% | 57.2% | ||
| Q3 24 | 15.3% | 20.1% | ||
| Q2 24 | 15.7% | 25.3% |
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 48.9% | ||
| Q3 25 | 23.5% | 36.9% | ||
| Q2 25 | 15.5% | 25.0% | ||
| Q1 25 | 10.2% | 33.7% | ||
| Q4 24 | 13.6% | 54.7% | ||
| Q3 24 | 13.5% | 19.2% | ||
| Q2 24 | 14.3% | 24.2% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $1.01 | ||
| Q3 25 | $0.70 | $0.76 | ||
| Q2 25 | $0.45 | $0.50 | ||
| Q1 25 | $0.27 | $0.67 | ||
| Q4 24 | $0.37 | $1.10 | ||
| Q3 24 | $0.34 | $0.38 | ||
| Q2 24 | $0.35 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $55.9M |
| Total DebtLower is stronger | — | $8.2B |
| Stockholders' EquityBook value | $2.7B | $11.0B |
| Total Assets | $6.3B | $20.7B |
| Debt / EquityLower = less leverage | — | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $55.9M | ||
| Q3 25 | $1.8B | $93.1M | ||
| Q2 25 | $1.2B | $31.3M | ||
| Q1 25 | $904.9M | $39.8M | ||
| Q4 24 | $606.1M | $62.3M | ||
| Q3 24 | $621.2M | $28.6M | ||
| Q2 24 | $939.2M | $38.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $8.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $11.0B | ||
| Q3 25 | $2.7B | $11.1B | ||
| Q2 25 | $2.6B | $11.0B | ||
| Q1 25 | $2.3B | $11.0B | ||
| Q4 24 | $2.1B | $11.0B | ||
| Q3 24 | $2.0B | $10.9B | ||
| Q2 24 | $2.4B | $11.0B |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $20.7B | ||
| Q3 25 | $7.5B | $21.1B | ||
| Q2 25 | $7.3B | $21.0B | ||
| Q1 25 | $6.8B | $20.6B | ||
| Q4 24 | $6.5B | $20.8B | ||
| Q3 24 | $6.4B | $20.9B | ||
| Q2 24 | $6.8B | $19.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.75× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $387.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $387.0M | ||
| Q3 25 | $659.9M | $476.7M | ||
| Q2 25 | $303.0M | $359.5M | ||
| Q1 25 | $183.8M | $425.5M | ||
| Q4 24 | $301.4M | $354.2M | ||
| Q3 24 | $199.5M | $401.4M | ||
| Q2 24 | $279.4M | $396.9M |
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | — | ||
| Q3 25 | $579.4M | — | ||
| Q2 25 | $208.9M | — | ||
| Q1 25 | $96.8M | — | ||
| Q4 24 | $176.8M | — | ||
| Q3 24 | $88.3M | — | ||
| Q2 24 | $213.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 47.9% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 15.9% | — | ||
| Q3 24 | 8.9% | — | ||
| Q2 24 | 21.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 6.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.01× | ||
| Q3 25 | 2.33× | 1.65× | ||
| Q2 25 | 1.69× | 1.87× | ||
| Q1 25 | 1.74× | 1.66× | ||
| Q4 24 | 1.99× | 0.85× | ||
| Q3 24 | 1.48× | 2.80× | ||
| Q2 24 | 1.95× | 2.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
